Heart drug trial halted after only 6 patients
NCT ID NCT04723186
First seen May 31, 2026 · Last updated Jun 23, 2026 · Updated 2 times
Summary
This trial tested a new drug called MT1002 in 6 people having a heart procedure (PCI) after a heart attack. The goal was to see if it could safely control blood clotting. However, the study was stopped early, so we don't have enough information to know if the drug works or is safe.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE CORONARY SYNDROME are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
IU Health - BMH
Muncie, Indiana, 47303, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MT1002 (an injectable drug to prevent blood clots during heart procedures)
What this could lead to
If it had worked, MT1002 might have offered a new option to control blood clotting during heart procedures, potentially reducing complications.
What could go wrong
This was a very small, early-phase trial that was terminated early, so we have little data on safety or effectiveness. The drug may not work or could cause serious bleeding.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.